Raytheon awarded $71 million in Navy contracts for missile systems
ABBOTT PARK, Ill. - Abbott (NYSE: ABT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $223.67 billion, has released findings from its REFLECT studies indicating that its FreeStyle Libre continuous glucose monitoring (CGM) technology is linked to a significant decrease in hospitalizations due to heart complications for people with diabetes. According to InvestingPro data, the company maintains a strong financial health score of "GREAT," supporting its continued innovation in healthcare technology. The studies, utilizing data from the Swedish National Diabetes Register, show an 80% reduction in cardiovascular disease-related hospitalizations for Type 1 diabetes patients with no prior history of cardiovascular disease when using the Libre technology. For those with a history of such disease, the reduction was 49%. This breakthrough research comes as Abbott demonstrates strong market performance, with a 25.38% total return over the past year and robust revenue of $42.34 billion in the last twelve months.
Diabetes, affecting roughly 589 million people globally, is often associated with cardiovascular complications, which are a leading cause of mortality in diabetic patients. The REFLECT research examined a variety of cardiovascular conditions, including non-fatal heart attacks and strokes, coronary artery disease, heart failure, and cardiovascular death, which are prevalent in the diabetic population.
The use of CGM technology like Libre is now associated not only with better diabetes management but also with potentially lower healthcare costs due to fewer hospital admissions related to heart complications. David Nathanson, MD, PhD, one of the lead authors from Karolinska University Hospital in Sweden, highlighted the dual benefits of CGM technology in managing diabetes and its cardiovascular complications. He emphasized that CGMs offer real-time glucose level feedback, allowing individuals to proactively manage their health.
The REFLECT studies, funded by Abbott and published between October 2024 and April 2025, assessed the impact of CGM versus traditional blood glucose monitoring on hospitalization rates for metabolic and vascular complications in adults with Type 1 and insulin-treated Type 2 diabetes.
Abbott’s FreeStyle Libre technology has been at the forefront of diabetes care for over a decade and is currently used by more than 7 million people across 60 countries. The technology enables users to monitor their glucose levels in real-time, providing insights into how diet, activity, and insulin affect their glucose levels. With a gross profit margin of 56% and consistent dividend payments for 55 consecutive years, Abbott demonstrates strong financial fundamentals. InvestingPro analysis suggests the stock is currently trading near its Fair Value, making it an interesting watch for healthcare sector investors. For detailed insights and more exclusive tips about Abbott’s investment potential, explore the comprehensive Pro Research Report, available to InvestingPro subscribers.
This press release statement provides a significant update on the benefits of CGM technology in reducing cardiovascular risks for diabetic patients, offering a promising outlook for healthcare management in diabetes.
In other recent news, Abbott Laboratories has reported strong financial performance in its first-quarter results, with earnings per share (EPS) of $1.09, surpassing analyst expectations. The company achieved a 6.9% year-over-year organic sales growth, which rises to 8.3% when excluding COVID-19 testing revenue. Abbott’s Medical Devices segment showed particular strength, with organic sales growth of 12.6%, driven by a 30% increase in U.S. Continuous Glucose Monitoring sales. Despite a slight revenue miss, analysts remain optimistic, with TD Cowen, RBC Capital, and Piper Sandler all raising their price targets to $145, while UBS maintains a target of $148. The company’s reaffirmed 2025 guidance, despite facing tariff challenges, has been a key reassurance for investors. Analysts from firms like Bernstein SocGen and UBS have noted Abbott’s resilience and strategic initiatives to mitigate tariff impacts. Abbott’s ability to maintain and project growth in challenging macroeconomic conditions has been highlighted by multiple analysts. The company’s diversified operations and robust performance in the MedTech sector continue to support a positive outlook from the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.